Haemodynamic effects of ATP in dogs during hypoxia-induced pulmonary hypertension

被引:4
作者
Driessen, B
Haskins, SC
Pascoe, PJ
Tripp, LD
Reitan, JA
机构
[1] Univ Calif Davis, Vet Med Teaching Hosp, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Surg & Radiol Sci, Sch Vet Med, Davis, CA 95616 USA
[3] Univ Calif Davis, Sch Med, Dept Anesthesiol, Davis, CA 95616 USA
关键词
D O I
10.1046/j.1365-2885.1999.00206.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pulmonary hypertension may result from an increase in vascular resistance caused by persistent hypoxia. We have investigated the effects of adenosine triphosphate (ATP), administered into the pulmonary artery, on haemodynamic changes occurring in anaesthetized adult dogs subjected to acute hypoxic pulmonary vasoconstriction. Hypoxia alone (ventilation with 10% O-2/90% N-2) caused significant increases in mean pulmonary arterial blood pressure (PAP), central venous pressure (CVP), and cardiac index (CI) by 71, 102 and 38%, respectively. ATP (0.03-3.0 mu mol/kg/min approximate to 0.02-1.65 mg/kg/min), when infused under hypoxic conditions, significantly reduced both mean PAP and systemic arterial blood pressure (ABP) in a dose-dependent manner. The maximum decrease in mean PAP amounted to 20%; mean ABP, on the other hand, was decreased by up to 52% (P < 0.01). Heart rate, CI, CVP and pulmonary occlusion pressure were not dose-dependently affected by ATP, Our data indicate that while pulmonary arterial administration of ATP in mature dogs during hypoxic pulmonary hypertension causes dilation in the pulmonary vascular bed, it is even more effective in dilating the systemic vasculature. This result suggests a need for further evaluation and warrants cautious use of ATP in the treatment of hypoxic pulmonary hypertension in adult dogs.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 33 条
[1]  
BENUMOF J L, 1982, Anesthesiology (Hagerstown), V57, pA474, DOI 10.1097/00000542-198209001-00474
[2]  
BINET L, 1950, PRESSE MED, V58, P1201
[3]   BRADYKININ AND ATP STIMULATE L-ARGININE UPTAKE AND NITRIC-OXIDE RELEASE IN VASCULAR ENDOTHELIAL-CELLS [J].
BOGLE, RG ;
COADE, SB ;
MONCADA, S ;
PEARSON, JD ;
MANN, GE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (02) :926-932
[4]   USE OF ATP-MGCL2 IN THE EVALUATION AND TREATMENT OF CHILDREN WITH PULMONARY-HYPERTENSION SECONDARY TO CONGENITAL HEART-DEFECTS [J].
BROOK, MM ;
FINEMAN, JR ;
BOLINGER, AM ;
WONG, AF ;
HEYMANN, MA ;
SOIFER, SJ .
CIRCULATION, 1994, 90 (03) :1287-1293
[5]  
BULTMANN R, 1995, N-S ARCH PHARMACOL, V352, P477
[6]   INTEGRATION OF FACTORS CONTROLLING VASCULAR TONE - OVERVIEW [J].
BURNSTOCK, G .
ANESTHESIOLOGY, 1993, 79 (06) :1368-1380
[7]  
BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1
[8]   PHARMACOLOGICAL ANALYSIS OF ECTO-ATPASE INHIBITION - EVIDENCE FOR COMBINED ENZYME-INHIBITION AND RECEPTOR ANTAGONISM IN P-2X-PURINOCEPTOR LIGANDS [J].
CRACK, BE ;
BEUKERS, MW ;
MCKECHNIE, KCW ;
IJZERMAN, AP ;
LEFF, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (04) :1432-1438
[9]  
De Mey Jo G. R., 1998, Pharmacology and Toxicology, V83, P15
[10]  
DEMEY JG, 1982, J PHARMACOL EXP THER, V222, P166